Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: A retrospective study in Japan |
| |
| Authors: | Hirotsugu Kenmotsu Yasuhisa Ohde Takehito Shukuya Hirofumi Eida Hiroaki Akamatsu Akira Ono Yukiko Nakamura Asuka Tsuya Kyoichi Kaira Tateaki Naito Haruyasu Murakami Toshiaki Takahashi Tomohiro Maniwa Mitsuhiro Isaka Masahiro Endo Haruhiko Kondo Nobuyuki Yamamoto |
| |
| Affiliation: | 1. Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka 411-8777, Japan;2. Division of Thoracic Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka 411-8777, Japan;3. Division of Diagnostic Radiology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka 411-8777, Japan;1. National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan;2. Bach Mai Hospital, 78 Giai Phong, Dong Da, Hanoi, Vietnam;3. NCGM-BMH Medical Collaboration Center, 78 Giai Phong, Dong Da, Hanoi, Vietnam;4. Waseda University, 1-21-1 Nishi-Waseda, Shinjuku-ku, Tokyo 169-0051, Japan;1. Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan;2. First Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, 830-0011 Kurume, Japan;3. Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan;1. Department of Rehabilitation, Gunma University Hospital, Japan;2. Gunma University Graduate School of Health Sciences, Japan;3. Department of Respiratory Medicine, Maebashi Red Cross Hospital, Japan;1. Division of Respiratory and Allergy Medicine, Komaki City Hospital, Komaki, 1-20, Johbushi, Komaki City 485-8520, Japan;2. Division of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, 6-16-1 Tomioka-Higashi, Kanazawa-ku, Yokohama City 236-0051, Japan |
| |
| Abstract: | BackgroundThe efficacy of postoperative adjuvant cisplatin (CDDP)-based chemotherapy, such as the combination of CDDP and vinorelbine (VNR), has been established for surgically resected non-small-cell lung cancer (NSCLC). However, the optimal treatment schedule and dosage for CDDP and VNR are unknown. We evaluated patient compliance with and the safety of adjuvant chemotherapy of CDDP at 80 mg/m2 administered on day 1 plus VNR at 25 mg/m2 administered on days 1 and 8, every 3 weeks.MethodsMedical records of 100 surgically resected NSCLC patients, treated with a combination of CDDP and VNR at the Shizuoka Cancer Center between February 2006 and October 2011, were retrospectively reviewed.ResultsEighty-three (83%) patients completed the planned 4 cycles of CDDP plus VNR and 59 (59%) received the planned doses. Sixty-eight percent of the patients experienced a decreased neutrophil count (grade 3/4 toxicity); 1%, a decreased platelet count; and 4%, febrile neutropenia. No treatment-related deaths were noted in this study. Univariate analysis of the factors influencing patient compliance with this adjuvant chemotherapy showed that neither patient characteristics nor surgical procedure was significantly associated.ConclusionsOur results indicated that adjuvant chemotherapy with CDDP at 80 mg/m2 administered on day 1 plus VNR at 25 mg/m2 administered on days 1 and 8, every 3 weeks, was feasible for surgically resected NSCLC cases. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
